Biophytis (BPTSY) Stock Price, News & Analysis

Company Overview

Biophytis S.A. is a France-based clinical-stage biotechnology company focused on developing therapies for diseases associated with aging and physical decline. Its research programs target conditions affecting muscle function, respiratory health and other age-related disorders.

The company’s leading drug candidate is Sarconeos (BIO101), an orally administered small molecule being investigated for sarcopenia, a condition characterized by the progressive loss of muscle mass and strength. Biophytis has also evaluated BIO101 in other settings, including severe respiratory complications associated with COVID-19 and Duchenne muscular dystrophy. The company’s pipeline is based in part on bioactive compounds derived from plants.

Biophytis was founded in France in 2006 and conducts research and clinical-development activities in Europe and the United States. The company has been led by co-founder Stanislas Veillet, who serves as chief executive officer. As a development-stage biotechnology company, Biophytis’ activities are centered on advancing its candidates through clinical testing and regulatory evaluation.

Key Stats

• Today's Range: $0.25 to $0.25
• 50-Day Range: $0.25 to $0.25
• 52-Week Range: $0.00 to $2.08
• Volume: 10 shs
• Average Volume: 1,154 shs
• Market Capitalization: $586.50 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:BPTSY
• CIK: 1768946
• Web: www.biophytis.com
• Phone: 33-1-44-27-23-00
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.41
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($16.18) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 2,346,000
• Free Float: 338,000
• Market Cap: $586.50 thousand
• Optionable: N/A
• Beta: 2.46